262 related articles for article (PubMed ID: 10494491)
21. A comparison of latanoprost and timolol in primary open-angle glaucoma and ocular hypertension. A 12-week study.
Mishima HK; Masuda K; Kitazawa Y; Azuma I; Araie M
Arch Ophthalmol; 1996 Aug; 114(8):929-32. PubMed ID: 8694726
[TBL] [Abstract][Full Text] [Related]
22. A comparative clinical study of latanoprost and isopropyl unoprostone in Japanese patients with primary open-angle glaucoma and ocular hypertension.
Tsukamoto H; Mishima HK; Kitazawa Y; Araie M; Abe H; Negi A;
J Glaucoma; 2002 Dec; 11(6):497-501. PubMed ID: 12483094
[TBL] [Abstract][Full Text] [Related]
23. A 12 week study comparing the fixed combination of latanoprost and timolol with the concomitant use of the individual components in patients with open angle glaucoma and ocular hypertension.
Diestelhorst M; Larsson LI;
Br J Ophthalmol; 2004 Feb; 88(2):199-203. PubMed ID: 14736774
[TBL] [Abstract][Full Text] [Related]
24. Efficacy and tolerability of fixed-combination bimatoprost/timolol versus fixed-combination dorzolamide/brimonidine/timolol in patients with primary open-angle glaucoma or ocular hypertension: a multicenter, prospective, crossover study.
García-López A; Paczka JA; Jiménez-Román J; Hartleben C
BMC Ophthalmol; 2014 Dec; 14():161. PubMed ID: 25527295
[TBL] [Abstract][Full Text] [Related]
25. The additive intraocular pressure-lowering effect of latanoprost 0.005% daily once and pilocarpine 2% t.i.d. in patients with open-angle glaucoma or ocular hypertension. a 6-month, randomized, multicenter study. German Latanoprost Study Group.
Diestelhorst M
Graefes Arch Clin Exp Ophthalmol; 2000 May; 238(5):433-9. PubMed ID: 10901475
[TBL] [Abstract][Full Text] [Related]
26. Latanoprostene Bunod 0.024% versus Timolol Maleate 0.5% in Subjects with Open-Angle Glaucoma or Ocular Hypertension: The APOLLO Study.
Weinreb RN; Scassellati Sforzolini B; Vittitow J; Liebmann J
Ophthalmology; 2016 May; 123(5):965-73. PubMed ID: 26875002
[TBL] [Abstract][Full Text] [Related]
27. A 12-month, multicenter, randomized, double-masked, parallel-group comparison of timolol-LA once daily and timolol maleate ophthalmic solution twice daily in the treatment of adults with glaucoma or ocular hypertension.
Mundorf TK; Ogawa T; Naka H; Novack GD; Crockett RS;
Clin Ther; 2004 Apr; 26(4):541-51. PubMed ID: 15189751
[TBL] [Abstract][Full Text] [Related]
28. Fixed combination of latanoprost and timolol vs individual components for primary open-angle glaucoma or ocular hypertension: a randomized, double-masked study.
Higginbotham EJ; Olander KW; Kim EE; Grunden JW; Kwok KK; Tressler CS;
Arch Ophthalmol; 2010 Feb; 128(2):165-72. PubMed ID: 20142538
[TBL] [Abstract][Full Text] [Related]
29. Evaluation of travoprost as adjunctive therapy in patients with uncontrolled intraocular pressure while using timolol 0.5%.
Orengo-Nania S; Landry T; Von Tress M; Silver LH; Weiner A; Davis AA;
Am J Ophthalmol; 2001 Dec; 132(6):860-8. PubMed ID: 11730649
[TBL] [Abstract][Full Text] [Related]
30. Comparison of travoprost 0.0015% and 0.004% with timolol 0.5% in patients with elevated intraocular pressure: a 6-month, masked, multicenter trial.
Fellman RL; Sullivan EK; Ratliff M; Silver LH; Whitson JT; Turner FD; Weiner AL; Davis AA;
Ophthalmology; 2002 May; 109(5):998-1008. PubMed ID: 11986110
[TBL] [Abstract][Full Text] [Related]
31. An eight-week, multicentric, randomized, interventional, open-label, phase 4, parallel comparison of the efficacy and tolerability of the fixed combination of timolol maleate 0.5%/brimonidine tartrate 0.2% versus fixed combination of timolol maleate 0.5%/dorzolamide 2% in patients with elevated intraocular pressure.
Hatanaka M; Grigera DE; Barbosa WL; Jordao M; Susanna R
J Glaucoma; 2008 Dec; 17(8):674-9. PubMed ID: 19092465
[TBL] [Abstract][Full Text] [Related]
32. Additive intraocular pressure reduction effect of fixed combination of maleate timolol 0.5%/dorzolamide 2% (Cosopt) on monotherapy with latanoprost (Xalatan) in patients with elevated intraocular pressure: a prospective, 4-week, open-label, randomized, controlled clinical trial.
Hatanaka M; Reis A; Sano ME; Susanna R
J Glaucoma; 2010; 19(5):331-5. PubMed ID: 19730119
[TBL] [Abstract][Full Text] [Related]
33. Twice-daily 0.2% brimonidine-0.5% timolol fixed-combination therapy vs monotherapy with timolol or brimonidine in patients with glaucoma or ocular hypertension: a 12-month randomized trial.
Sherwood MB; Craven ER; Chou C; DuBiner HB; Batoosingh AL; Schiffman RM; Whitcup SM
Arch Ophthalmol; 2006 Sep; 124(9):1230-8. PubMed ID: 16966616
[TBL] [Abstract][Full Text] [Related]
34. Adjunctive therapy with brinzolamide 1% ophthalmic suspension (Azopt) in patients with open-angle glaucoma or ocular hypertension maintained on timolol therapy.
Shin D
Surv Ophthalmol; 2000 Jan; 44 Suppl 2():S163-8. PubMed ID: 10665519
[TBL] [Abstract][Full Text] [Related]
35. Changes in ocular surface caused by antiglaucomatous eyedrops: prospective, randomised study for the comparison of 0.5% timolol v 0. 12% unoprostone.
Shimazaki J; Hanada K; Yagi Y; Yamagami J; Ishioka M; Shimmura S; Tsubota K
Br J Ophthalmol; 2000 Nov; 84(11):1250-4. PubMed ID: 11049949
[TBL] [Abstract][Full Text] [Related]
36. A 1-year study of brimonidine twice daily in glaucoma and ocular hypertension. A controlled, randomized, multicenter clinical trial. Chronic Brimonidine Study Group.
Schuman JS; Horwitz B; Choplin NT; David R; Albracht D; Chen K
Arch Ophthalmol; 1997 Jul; 115(7):847-52. PubMed ID: 9230823
[TBL] [Abstract][Full Text] [Related]
37. Low incidence of iris pigmentation and eyelash changes in 2 randomized clinical trials with unoprostone isopropyl 0.15%.
McCarey BE; Kapik BM; Kane FE;
Ophthalmology; 2004 Aug; 111(8):1480-8. PubMed ID: 15288975
[TBL] [Abstract][Full Text] [Related]
38. Efficacy and safety of preservative-free timolol 0.1% gel in open-angle glaucoma and ocular hypertension in treatment-naïve patients and patients intolerant to other hypotensive medications.
Lazreg S; Merad Z; Nouri MT; Garout R; Derdour A; Ghroud N; Kherroubi R; Meziane M; Belkacem S; Ouhadj O; Baudouin C; Tiar M
J Fr Ophtalmol; 2018 Dec; 41(10):945-954. PubMed ID: 30477719
[TBL] [Abstract][Full Text] [Related]
39. [A comparison between latanoprost and timolol in treatment of patients with primary open-angle glaucoma and ocular hypertension].
Peng D; Li S; Li M; Shao H; Sun X; Sheng Y; Yu K; Fu P; Guo W; Meng F; Xu C; Zhu Z
Zhonghua Yan Ke Za Zhi; 2000 Jul; 36(4):285-8. PubMed ID: 11853616
[TBL] [Abstract][Full Text] [Related]
40. Comparative effects of latanoprost (Xalatan) and unoprostone (Rescula) in patients with open-angle glaucoma and suspected glaucoma.
Sponsel WE; Paris G; Trigo Y; Pena M
Am J Ophthalmol; 2002 Oct; 134(4):552-9. PubMed ID: 12383812
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
